Estrogen Treatment After Ovariectomy Protects Against Fatty Liver and May Improve Pathway-Selective Insulin Resistance
Pathway-selective insulin resistance where insulin fails to suppress hepatic glucose production but promotes liver fat storage may underlie glucose and lipid abnormalities after menopause. We tested the mechanisms by which estrogen treatment may alter the impact of a high-fat diet (HFD) when given at the time of ovariectomy (OVX) in mice. Female C57BL/6J mice underwent sham operation, OVX, or OVX with estradiol (E2) treatment and were fed an HFD. Hyperinsulinemic-euglycemic clamps were used to assess insulin sensitivity, tracer incorporation into hepatic lipids, and liver triglyceride export. OVX mice had increased adiposity that was prevented with E2 at the time of OVX. E2 treatment increased insulin sensitivity with OVX and HFD. In sham and OVX mice, HFD feeding induced fatty liver, and insulin reduced hepatic apoB100 and liver triglyceride export. E2 treatment reduced liver lipid deposition and prevented the decrease in liver triglyceride export during hyperinsulinemia. In mice lacking the liver estrogen receptor α, E2 after OVX limited adiposity but failed to improve insulin sensitivity, to limit liver lipid deposition, and to prevent insulin suppression of liver triglyceride export. In conclusion, estrogen treatment may reverse aspects of pathway-selective insulin resistance by promoting insulin action on glucose metabolism but limiting hepatic lipid deposition.
With overnutrition, insulin resistance impairs insulin’s ability to suppress gluconeogenesis resulting in fasting hyperglycemia (1,2). By contrast, insulin robustly promotes liver fatty acid synthesis and decreases fatty acid oxidation (3–6). In fasting, this fatty liver increases triglyceride secretion in the form of VLDL and subsequently leads to decreased HDL (3,4,6–8). Insulin signaling also promotes degradation of apolipoprotein (apo)B100 in the liver, thus limiting secretion of VLDL from the liver (9). In these studies, we define how estrogen treatment may modulate pathway-selective insulin resistance and the development of fatty liver with high-fat diet (HFD) feeding in mice.
Premenopausal women are protected from the cardiovascular complications of obesity compared with BMI-matched men. This protection may relate to estrogen’s ability to limit liver fat accumulation, thus preventing hepatic insulin resistance (10,11). The triglyceride content of VLDL in women is increased by ∼70% compared with men without a difference in VLDL particle number (12–14). In insects, birds, and fish, estrogen-like pathways increase transport of triglyceride from the liver to facilitate egg development (15). Estrogen also promotes fatty acid oxidation in the liver. During menopause, liver lipids accumulate in the liver. We propose that estrogen treatment might promote fatty acid oxidation and increase the efficiency triglyceride export out of the liver, which might limit liver fat and improve glucose metabolism with HFD feeding.
In these studies, we define the mechanisms by which estrogen treatment at the time of surgical menopause (ovariectomy [OVX]) might improve the regulation of glucose and triglyceride metabolism. The metabolic effects of estrogen with regard to body weight regulation and fat storage are largely mediated by estrogen receptor α (ERα) (16,17). Mice with global ERα deletion have increased adiposity and insulin resistance (11,18,19). ERα signaling is also involved in LDL and HDL kinetics (20), protecting against the β-cell dysfunction that can accompany obesity (21) and integrating nutritional signaling (16). The role of liver ERα with regard to hepatic glucose and lipid metabolism is not well defined. We found that estrogen treatment reduces insulin-mediated liver fat storage and reduces diacylglycerol content and yet promotes insulin action with regard to glucose metabolism. This protective effect of estrogen treatment requires intact hepatic estrogen signaling through ERα. By contrast, we found that hepatic estrogen singling is not required for the effects of estrogen treatment on body weight and adiposity.
RESEARCH DESIGN AND METHODS
Seven-week-old female C57BL/6J mice (17–19 g, strain 000664; The Jackson Laboratory, Bar Harbor, ME) were housed at 22 ± 1°C in a 12:12-h light:dark cycle. Mice with liver-specific deletion of ERα on a C57BL/6J background (LKO) were made by breeding ERα flox/flox mice with mice expressing cre recombinase under the control of the albumin promoter (The Jackson Laboratory) (16,22,23). Protocols were approved by the institutional animal care and use committee at Vanderbilt University.
Mice were matched for body composition (n = 6–10 per group) and underwent sham operation, bilateral OVX, or OVX with a subcutaneous implantation of 17β-estradiol sustained release tablet at the time of OVX (0.25 mg/pellet, 60-day release; Innovative Research of America, Sarasota, FL). All mice were maintained on an HFD (cat. no. D08060104, 60% fat from lard, 20% protein, 20% carbohydrate from corn starch, 5.24 kcal/g; Research Diets).
After 5 weeks of HFD feeding, catheters were implanted by the Vanderbilt Mouse Metabolic Phenotyping Center in the left common carotid artery and right jugular vein for sampling and infusions as previously described (24).
Five to seven days after catheter placement, hyperinsulinemic-euglycemic clamps were performed in unrestrained 5-h–fasted mice. A primed (4.80 μCi) continuous (0.1067 μCi/min) infusion of U-14C-glycerol was initiated at t = −180 min (9:00 a.m.) and continued for the duration of the study. A primed (5.4 μCi) continuous (0.135 μCi/min) infusion of 3-3H-glucose was initiated at t = −90 min. The period between t = −180 and t = 0 allowed us to assess basal tracer incorporation into VLDL and glucose production. This basal period was followed by hyperinsulinemia started at t = 0 (4 mU/kg/min; Humulin R; Eli Lilly, Indianapolis, IN). At t = 0 min, the infusion rate was increased to 0.27 μCi/min. Euglycemia (∼150 mg/dL) was maintained by measuring blood glucose every 10 min starting at t = 0 min and adjusting the infusion of 50% dextrose as necessary. Mice received saline-washed erythrocytes from donors to prevent a fall in hematocrit. At t = 120 min, mice were killed and tissues were flash frozen. To obtain non–insulin-treated samples, a parallel set of experiments was performed in which mice were fed an HFD for 6 weeks, fasted 5 h, and then killed.
Plasma processing and calculations.
Insulin levels were determined by ELISA (cat. no. EZRMI-13K; Millipore, St. Charles, MO). Plasma 14C-triglyceride activities were divided by plasma triglyceride to define triglyceride-specific activity. In the fasting state, the triglyceride-specific activity is an index of VLDL flux. 3-3H-glucose activities were determined by liquid scintillation counting after plasma deproteinization. Glucose Rd and endogenous glucose production (EndoRa) were determined using non–steady state equations, and insulin sensitivity index was calculated as previously described (24–26).
Liver triglyceride content analysis.
Liver neutral lipids were stained with oil red O. Liver lipid was extracted using Folch methodology, and triglyceride and diacylglycerol were separated by thin-layer chromatography (TLC) as previously described (27). Total liver triglyceride amount was quantified using triglycerides GPO reagents according to the manufacturer’s protocol (Cliniqa); diacylglycerol amounts were evaluated using the same reagents and protocols by adjusting the standard value of glycerol. 14C-triglyceride and 14C-diacylglycerol were determined by scintillation counting after TLC separation and normalized to tissue weight.
Western blots were performed as previously described (28). Antibodies for AMP kinase (AMPK)α (cat. no. 2603), phosphorylated AMPKα (172Thr, cat. no. 2535), AMPKβ (cat. no. 4150), and phospho-AMPKβ (108Ser, cat. no. 4181) were from Cell Signaling (Beverly, MA); antibodies for diacylglycerol acyltransferase (DGAT)1 (sc-31680), DGAT2 (sc-66859), and β-actin (sc-47778) were from Santa Cruz Biotech (Santa Cruz, CA); antibody for ApoB100 was from LifeSpan BioSciences (LS-c20729). Anti-MTP antibody was provided by Dr. Larry Swift (29). Anti-mouse or anti-rabbit antibody was incubated with the dilution of 1:15,000 at room temperature for 1 h. Imaging and densitometry were performed using the Odyssey imaging system (LI-COR Biosciences, Lincoln, NE) and ImageJ processing program.
Data are presented as means ± SD. Differences between groups were determined by ANOVA followed by Tukey post hoc tests or by Student t test as appropriate. Significance was considered as P < 0.05.
Estrogen treatment at the time of OVX improves diet-induced obesity and insulin sensitivity.
For definition of the effects of estrogen treatment on obesity, dyslipidemia, and glucose metabolism, sham, OVX, or OVX+E2 mice were put on an HFD for a total of 6 weeks. We found that sham mice had a 32% increase in body weight and a 46% increase in adiposity (Fig. 1A and B) (P < 0.05 for both compared with baseline) and OVX mice had a 77% increase in body weight and 278% increase in adiposity after HFD feeding (Fig. 1A and B) (P < 0.05 for both). By contrast, estrogen-treated mice did not gain weight or have increased adiposity with OVX and HFD feeding (Fig. 1A and B). Thus, the absence of ovarian hormones predisposes to weight gain on HFD, and estrogen treatment was associated with reduced adiposity with OVX and HFD.
We evaluated the impact of OVX and estrogen treatment on serum lipids. Loss of ovarian hormones by OVX increased the fasting plasma cholesterol concentration compared with sham mice, which was prevented with estrogen treatment (Fig. 1C). Serum triglyceride levels were elevated with HFD feeding in sham mice compared with a group of chow-fed female controls (45 ± 7 mg/dL [not shown on the figure]); OVX did not further increase fasting serum triglyceride compared with HFD-fed sham mice. Mice with estrogen treatment did not have elevated serum triglyceride after OVX and HFD, and triglyceride levels were similar to those of chow-fed female controls (Fig. 1D) (45 ± 7 mg/dL for chow-fed female controls).
To obtain an index of what estrogen treatment did to insulin sensitivity, we examined fasting glucose and insulin levels. In sham mice with HFD feeding, fasting insulin levels were increased approximately threefold compared with chow-fed female controls (Fig. 1E) (10 ± 2 μU/mL for chow-fed controls [not shown in Fig. 1]). Fasting insulin levels were further increased in OVX mice. By contrast, estrogen treatment was associated with lower fasting insulin (Fig. 1E). There were no differences in fasting glucose levels between groups (Fig. 1F). These findings demonstrate that estrogen treatment was associated with a reduction in fasting insulin proportional to adiposity.
Insulin regulation of hepatic and peripheral glucose metabolism is maintained with HFD feeding with estrogen treatment after OVX.
We designed a study to assess baseline hepatic glucose and triglyceride secretion and then initiated a hyperinsulinemic-euglycemic clamp to assess both insulin sensitivity and insulin’s ability to suppress hepatic glucose production and triglyceride secretion (Fig. 2A). Blood glucose was matched between groups (Fig. 2B). The glucose infusion rate (GIR) required to maintain euglycemia is proportional to insulin sensitivity. We observed the lowest GIR in OVX mice and the highest GIR in OVX+E2 mice, and the GIR for sham mice was significantly higher than that for OVX (Fig. 2C). We also defined an insulin sensitivity index between groups by normalizing GIR to the plasma insulin concentration during the clamp period. Plasma insulin levels during the clamp were as follows: sham 68 ± 2 μU/mL, OVX 84 ± 20 μU/mL, and OVX+E2 47 ± 10 μU/mL. The insulin sensitivity index was significantly higher in OVX+E2 mice than in the other two groups (Fig. 2D). These data demonstrate that estrogen treatment improves insulin sensitivity after OVX and HFD.
We assessed whole-body and liver glucose metabolism during the clamp using a 3-3H-glucose tracer. Basal EndoRa was suppressed by hyperinsulinemia during the clamp in sham mice (Fig. 2E). By contrast, insulin-mediated suppression of EndoRa was impaired after OVX (Fig. 2E). Estrogen treatment was associated with improved ability of insulin to suppress EndoRa after OVX and HFD (Fig. 2E). Glucose Rd during the clamp was significantly higher with estrogen treatment in comparison with sham and OVX mice (Supplementary Fig. 1A). Thus, estrogen treatment improves hepatic and peripheral insulin action with regard to glucose metabolism after OVX.
Estrogen treatment does not augment insulin-dependent suppression of tracer incorporation into serum triglyceride.
To evaluate the impact of estrogen treatment on insulin regulation of liver triglyceride production, we monitored plasma triglyceride and 14C-triglyceride–specific activity during fasting and hyperinsulinemic clamps. In all three groups, plasma triglyceride gradually decreased with the duration of fasting and did not decrease further during hyperinsulinemic clamps (Fig. 2F). For all groups of mice, plasma 14C-triglyceride–specific activity leveled off between t = −30 and t = 0 min (Fig. 2F). In OVX mice, this plateau was maintained during hyperinsulinemia. However, in OVX+E2 mice, 14C-triglyceride–specific activity failed to plateau during the hyperinsulinemic period. Sham mice had an intermediate phenotype (Fig. 2G). Together, these data suggest that estrogen treatment limits the ability of hyperinsulinemia to restrain the efficiency of liver 14C-triglyceride secretion, an index of VLDL secretion in these fasted mice.
The estrogen-dependent maintenance of tracer incorporation into serum triglyceride during hyperinsulinemia should then limit the deposition of lipid in the liver.
Estrogen treatment improves fatty liver and reduces liver diacylglycerol deposition during hyperinsulinemia.
Fatty liver and the accumulation of diacylglycerol may promote the development of hepatic insulin resistance (30). HFD feeding increased liver triglyceride 2.1-fold in sham mice (Fig. 3A and B) (17.0 ± 3.8 μg/mg) compared with chow-fed female controls (8.0 ± 2.1 μg/mg [not shown in Fig. 3]). Liver triglyceride accumulation was more pronounced in OVX mice (24.7 ± 5.2 μg/mg). Estrogen treatment was associated with lower liver triglyceride with HFD and OVX (OVX+E2 8.4 ± 3.1 μg/mg). In OVX mice, in parallel with increased liver triglyceride content, HFD feeding significantly increased liver total diacylglycerol levels (Fig. 3D). The liver diacylglycerol content in sham mice fed with HFD was 2.7-fold higher than in chow-fed female C57 mice (HFD 0.62 μg/mg vs. chow 0.23 μg/mg, P < 0.05). Liver diacylglycerol content was not further increased by OVX but was lower in estrogen-treated mice after OVX (Fig. 3D).
We determined liver triglyceride and diacylglycerol deposition by measuring the incorporation of 14C-glycerol into liver triglyceride (Fig. 3C) after the hyperinsulinemic clamps. The liver 14C-triglyceride in OVX mice was 1.4-fold higher than in sham mice. Triglyceride deposition was lower in estrogen-treated mice (65% less than OVX and 49% less than sham mice, P < 0.05 for both). Similar to triglyceride deposition, estrogen was associated with lower diacylglycerol deposition after OVX (indicated by 14C-diacylglycerol) (Fig. 3E). These results suggest that estrogen treatment reduced liver triglyceride and diacylglycerol deposition associated with OVX and HFD. Liver levels of DGAT1/2 did not change between groups during either fasting or hyperinsulinemia (Supplementary Fig. 2). The reduced liver triglyceride and liver triglyceride deposition in OVX+E2 mice (Fig. 3) is consistent with the maintenance of tracer incorporation into serum triglyceride during hyperinsulinemia (Fig. 2G).
Estrogen treatment blocks insulin signaling to liver acetyl-CoA carboxylase.
Acetyl-CoA carboxylase (ACC) catalyzes the first step of fatty acid synthesis. Liver-specific deletion of ACC reduces hepatic triglyceride accumulation (31). We found that baseline ACC levels were elevated in OVX mice compared with sham and OVX+E2 mice (Fig. 4A and B). Increased ACC along with 14C-triglyceride levels (Fig. 4) suggests a contribution of triglyceride synthesis to liver fat deposition in mice without ovarian hormones. Phosphorylation of ACC (pACC) is an index of increased fatty acid oxidation and decreased fatty acid synthesis. We found increased pACC in non–insulin treated mice after OVX (Fig. 4A and C), consistent with other studies showing increased fatty acid oxidation associated with triglyceride accumulation in the liver (32,33).
After 2 h of hyperinsulinemia, pACC was decreased in sham mice. This decrease was less evident in mice after OVX, indicated by percent suppression by insulin (Fig. 4C). By contrast, pACC was increased in OVX+E2 mice despite hyperinsulinemia in the clamp study. This result suggests that estrogen treatment may decrease fatty acid synthesis and maintain fatty acid oxidation in the setting of hyperinsulinemia. In muscle, estrogen is known to activate AMPK and promote fatty acid oxidation (34). Our results do not appear to be mediated by AMPK, which was unchanged between groups (Supplementary Fig. 3).
Estrogen treatment blocks the effects of hyperinsulinemia to reduce hepatic apoB100 and phospholipid transfer protein.
To define the mechanisms for maintained tracer incorporation into serum triglyceride during hyperinsulinemia in OVX+E2 mice, we compared levels of hepatic proteins involved in the regulation of VLDL secretion. During fasting, liver apoB100 protein levels were similar in sham, OVX, and OVX+E2 mice (Fig. 4D and E). Insulin decreased apoB100 for both sham and OVX mice (Fig. 4D and E). We found that insulin failed to decrease hepatic apoB100 in OVX+E2 mice, which was consistent with the accompanying maintenance of tracer incorporation into serum triglyceride during hyperinsulinemia (Fig. 2G). ApoB100 secretion is controlled in part by lipidation in endoplasmic reticulum by microsomal triglyceride transfer protein (MTP). We found that MTP levels were not changed between baseline and hyperinsulinemia or between groups (Fig. 4D and F). Phospholipid transfer protein (PLTP) promotes VLDL secretion by transferring phospholipids onto VLDL particles (35). PLTP protein levels were reduced during hyperinsulinemia in sham and OVX mice. Insulin-mediated decrease in PLTP was prevented by estrogen treatment in mice (Fig. 4D and G). The results with PLTP are qualitatively similar to the liver apoB100 levels in these groups. This suggests that estrogen may promote lipid loading of apoB100 to maintain VLDL secretion in the setting of hyperinsulinemia, which would limit hepatic lipid deposition.
Hepatic ERα signaling is required for estrogen to improve pathway-selective insulin resistance associated with HFD.
We used female mice with liver-specific knockout (LKO) of ERα to define the contribution of whole-body versus hepatic estrogen signaling toward the improvements in insulin resistance and dyslipidemia seen with estrogen treatment after OVX. In LKO mice, liver ERα expression was reduced >90% from whole-liver extracts but unchanged in muscle or adipose tissue (Fig. 5A). The LKO female mice had body weight, adiposity, fasting triglyceride, and fasting glucose similar to those of their littermates on a chow diet (Supplementary Table 1).
As was observed in wild-type C57BL/6J mice, OVX was associated with increased body weight and adiposity compared with sham mice (Fig. 5B and C). Also like wild-type mice, estrogen treatment was associated with reduced body weight and reduced adiposity after OVX in LKO mice (Fig. 5B and C). These results demonstrate that the ability of estrogen treatment to protect from OVX- and diet-induced adiposity does not require intact hepatic ERα signaling.
In contrast to wild-type littermates, in which estrogen treatment reduced fasting triglyceride, in OVX LKO mice estrogen treatment significantly increased fasting triglyceride (Supplementary Fig. 4A). Fasting plasma cholesterol concentration was increased with OVX in both wild-type and LKO mice and reduced with estrogen treatment in both groups (Supplementary Fig. 4B). These results suggest that hepatic estrogen signaling is required for estrogen treatment to maintain low serum triglyceride after OVX. By contrast, reduction of fasting cholesterol does not appear to require liver estrogen signaling and was more closely associated with the reduced adiposity seen in both LKO and wild-type mice with estrogen treatment.
Estrogen treatment lowered insulin levels in both LKO mice and their wild-type littermates (Supplementary Fig. 4D). Fasting glucose values were not different between groups (Supplementary Fig. 4C). Hyperinsulinemic clamp studies showed that estrogen treatment after OVX improved insulin sensitivity in wild-type littermates (Fig. 5E and Supplementary Fig. 4E). In contrast, the ability of estrogen treatment to improve insulin sensitivity after OVX was blunted in LKO mice (Fig. 5E [GIR] and Supplementary Fig. 4E [insulin sensitivity index]). Estrogen treatment did not improve insulin suppression of EndoRa in LKO mice (Fig. 5F). Additionally, estrogen treatment did not prevent insulin suppression of 14C tracer incorporation into serum triglyceride (Fig. 5G). These results suggest that the ability of E2 treatment to block insulin-mediated triglyceride secretion from the liver requires hepatic ERα. Based on this insulin suppression of triglyceride secretion, we expected to find increased liver fat in E2-treated LKO mice.
Liver ERα signaling is required to prevent liver fat and diacylglycerol accumulation.
In the absence of hepatic ERα signaling, liver 14C-triglyceride deposition and triglyceride accumulation remained high with estrogen treatment in LKO mice (Fig. 6A and B), which was 2.2-fold (P < 0.05) higher than in E2-treated wild-type controls (Fig. 3B and C). Estrogen treatment was unable to reduce total diacylglycerol and 14C-diacylglycerol in LKO mice (Fig. 6C and D). The ability of estrogen to block the effects of insulin with regard to ACC dephosphorylation and protein amounts of ApoB100 and PLTP was also lost in E2 LKO mice (Fig. 6E and Supplementary Fig. 5).
Thus, despite a lean body composition in E2 LKO mice, liver ERα signaling was required for the ability of estrogen treatment to reduce triglyceride and diacylglycerol accumulation in the liver. Taken together, these results suggest that estrogen treatment acts through hepatic ERα to prevent fatty liver by suppressing triglyceride synthesis, maintaining the efficiency of triglyceride secretion from the liver (Fig. 7). In addition, hepatic ERα appears to be required for estrogen to improve insulin action on glucose metabolism. Thus, while E2 treatment maintained lean body composition after OVX, E2 treatment failed to reverse pathway-selective insulin resistance in the absence of hepatic ERα.
Overnutrition results in pathway-selective insulin resistance, where insulin signaling is impaired with regard to glucose metabolism, yet intact with regard to fatty acid and liver triglyceride storage. We designed in vivo studies to simultaneously study both aspects of this biology (Fig. 7). We found HFD feeding after OVX produced such pathway-selective insulin resistance where insulin failed to suppress hepatic glucose production, yet insulin was able to reduce hepatic apoB content, maintain ACC activity, and suppress tracer incorporation into serum triglyceride. This predisposed mice to hepatic triglyceride and diacylglycerol accumulation. Estrogen treatment at the time of surgical menopause was associated with improvements in pathway-selective insulin resistance. Estrogen treatment restrained liver triglyceride deposition, prevented insulin signaling to apoB, and maintained triglyceride export from the liver. This was associated with a reduction in liver triglyceride and diacylglycerol content with HFD feeding. Reciprocally, estrogen treatment augmented the ability of insulin to regulate hepatic and peripheral glucose metabolism. Thus, estrogen treatment improved some aspects of pathway-selective insulin resistance in the liver associated with HFD feeding.
In these studies, we also defined tissue-specific roles of estrogen treatment in the setting of HFD feeding after OVX. Estrogen treatment with OVX prevented weight gain and increased adiposity with HFD feeding. This effect of estrogen treatment was seen both in wild-type mice and in LKO mice, indicating that hepatic estrogen is dispensable for body weight regulation with estrogen treatment. These findings are consistent with known effects of estrogen to reduce food intake and adiposity in the central nervous system and promote fatty acid oxidation in peripheral tissues (34,36,37). Despite lean body composition, however, estrogen-treated LKO mice had fatty liver, and estrogen treatment resulted in only modest improvement in whole-body insulin sensitivity compared with OVX LKO mice. Without hepatic estrogen signaling, there was also severe hepatic insulin resistance indicated by impaired insulin suppression of hepatic glucose production, even in lean estrogen-treated mice after OVX (Fig. 5F). Thus, hepatic estrogen signaling appears to be important for the metabolic effects of estrogen treatment with regard to preventing fatty liver and maintaining glucose homeostasis. These results help dissociate estrogen’s effects on body weight from estrogen regulation of insulin sensitivity.
We found that estrogen treatment reduces fatty liver by disrupting insulin’s effects to promote liver fat storage on several levels. The drug tamoxifen, an estrogen antagonist, increases hepatic steatosis in some breast cancer patients (38). Global loss of estrogen signaling also increases liver fat in several models, including humans with ERα mutations, rodents after OVX, mice with global ERα knockout, and mice lacking aromatase (19,39,40). Here, we report an underlying mechanism by which estrogen signaling may decrease liver fat (Fig. 7). In our studies, estrogen treatment after OVX reduced liver fat accretion by 1) limiting fat synthesis indicated by 14C deposition into liver triglyceride and diacylglycerol, 2) blocking insulin signaling to apoB, ACC, and PLTP, and 3) maintaining the efficiency of triglyceride export from the liver in the setting of hyperinsulinemia, indicated by preserved tracer incorporation into serum triglyceride and a failure of insulin to reduce hepatic apoB. The net effect was reduced liver triglyceride and diacylglycerol compared with OVX mice. This decrease in liver triglyceride and diacylglycerol may have contributed to the improved ability of insulin to suppress hepatic glucose production and improve insulin sensitivity.
The tissue-specific effects of estrogen treatment seen in these results may have implications for human diseases. The phenotype of E2 LKO mice with HFD feeding mimics the insulin resistance, dyslipidemia, and hepatic steatosis associated with lean body composition in patients with lipodystrophy (41). The tissue-specific estrogen/ERα signaling seen in our model of estrogen treatment might also be helpful for understanding mechanisms for the negative effects of late estrogen treatment postmenopause with regard to cardiovascular disease. Estrogen treatment when added after insulin resistance is established in peripheral tissues may make dyslipidemia worse by promoting VLDL flux that cannot be matched with efficient VLDL clearance.
For women before menopause, sex-phenotype differences confer cardiovascular protection compared with men, which may relate to improvements in metabolic complications of obesity (13,42–45). The goal of postmenopausal hormone replacement in clinical use has been to recapitulate the protective effects of the premenopausal state; however, large-scale trials have failed to show a substantial reduction in cardiovascular events (46–48). Selectively targeting liver estrogen signaling may decrease the metabolic complications of obesity and avoid some of the harmful effects of estrogen replacement in peripheral tissues such as the vascular endothelium.
This work was supported by the Department of Veterans Affairs, the American Heart Association (10GRNT3650024), the Atlantic Philanthropies, the American Diabetes Association (1-09-IG-01), the John A. Hartford Foundation, the Association of Specialty Professors, the Vanderbilt Diabetes Research and Training Center Pilot and Feasibility Program (DK20593), and the Vanderbilt Digestive Diseases Research Center Pilot and Feasibility Program (DK058404). L.Z. was supported by the Canadian Institutes of Health Research Strategic Training Program.
No potential conflicts of interest relevant to this article were reported.
L.Z. researched data, wrote the manuscript, and contributed to discussion of data. W.C.B. and Q.C. researched data, reviewed and edited the manuscript, and contributed to discussion of data. A.K., P.C., and O.P.M. contributed to general discussion, reviewed and edited the manuscript, and contributed to discussion of data. J.M.S. wrote and edited the manuscript and contributed to discussion of data. J.M.S. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Parts of this study were presented in abstract form at the 71st Scientific Sessions of the American Diabetes Association, San Diego, California, 24–28 June 2011.
The authors acknowledge excellent assistance by the Vanderbilt Mouse Metabolic Phenotyping Center (DK59637) and the Vanderbilt Hormone Assay and Analytical Services Core (DK59637 and DK20593). Liver lipid was stained at the Translational Pathology Shared Resource at Vanderbilt-Ingram Cancer Center. The authors thank Dr. Vivian Siegel of Vanderbilt University School of Medicine for critical reading of the manuscript.
This article contains Supplementary Data online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-1718/-/DC1.
- Received December 9, 2011.
- Accepted August 6, 2012.
- © 2013 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.